Clinical features of responders to mepolizumab in eosinophilic chronic rhinosinusitis and the outcomes post treatment cessation

美波利祖马布 医学 慢性鼻-鼻窦炎 嗜酸性 鼻息肉 疾病 内科学 皮肤病科 嗜酸性粒细胞 病理 哮喘
作者
Jacqueline Ho,Sophie Walter,Raquel Alvarado,Jessica W. Grayson,Raewyn G. Campbell,Larry Kalish,Raymond Sacks,William A. Sewell,Janet Rimmer,Richard J. Harvey
出处
期刊:Australian journal of otolaryngology [AME Publishing Company]
卷期号:7
标识
DOI:10.21037/ajo-23-28
摘要

Background: Recent studies have shown that mepolizumab is an effective treatment in the management of chronic rhinosinusitis with nasal polyposis (CRSwNP). Defining which patients will benefit from this treatment is essential in guiding its role in the multimodal approach to CRSwNP and eosinophilic chronic rhinosinusitis (eCRS). The aim of this study is to define the clinical and disease features of those patients who report benefit from therapy compared to non-responders. Methods: A prospective phase 2 clinical trial was undertaken with a single-arm of non-blinded patients with open label therapy with mepolizumab (trial registration ID ACTRN12618000113257) from May 2019 to November 2020. Patients underwent treatment with mepolizumab 100 mg 4-weekly for 6 months. Data was collected at baseline and at 4, 8, 12, 16, 20 and 24 weeks of treatment, as well as 4 months post their last mepolizumab dose. Data collected included patient demographics, blood eosinophil count (cells/L), tissue histopathology outcomes [inflammation severity, type, eosinophil density (cell/HPF)], functional outcomes [endoscopic findings, nasal nitric oxide (nNO), fractional exhaled nitric oxide (FeNO)] and patient reported outcome measures [including Sino-Nasal Outcome Test 22-item (SNOT-22), Asthma Control Questionnaire 5-item (ACQ-5), nasal obstruction visual analogue scores (VAS) and nasal function VAS]. Responders were defined as those patients having a ≥1 improvement in a 13-point ordinal overall nasal function score. Results: Twenty patients were assessed (age 47.7±14.5 years and 50% female). All patients had prior sinus surgery (4.1±3.5 years) and all had comorbid asthma. Fourteen patients (70%) were classed as responders to mepolizumab therapy. Responders were associated with higher baseline symptom burden: SNOT-22 (51.3±17.3 vs. 30.7±19.1, P=0.03), ACQ-5 (2.3±1.2 vs. 1.2±0.5, P=0.03) and lower baseline nNO (300.4±169.7 vs. 645.0±318.7 parts per billion, P=0.005). Within 3 months following cessation of mepolizumab, there was a deterioration of clinical outcomes including blood eosinophils, tissue eosinophils, SNOT-22 and ACQ-5. Conclusions: In eCRS, responders were likely to have more severe symptomatic disease at baseline and lower nNO. Cessation of mepolizumab is associated with deterioration of both objective and subjective markers.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
叶95完成签到 ,获得积分10
1秒前
玩命的怀绿完成签到,获得积分10
1秒前
小李子发布了新的文献求助10
1秒前
明明勇勇乐完成签到 ,获得积分10
1秒前
科研通AI6.2的应助被guantian采纳,获得10
5秒前
小白完成签到 ,获得积分10
5秒前
小新完成签到 ,获得积分10
6秒前
lili完成签到 ,获得积分10
7秒前
幽默豆芽完成签到 ,获得积分10
7秒前
8秒前
锅锅完成签到 ,获得积分10
9秒前
zgd完成签到 ,获得积分10
9秒前
杯中冰糖茶完成签到,获得积分10
10秒前
华理附院孙文博完成签到 ,获得积分0
11秒前
HW完成签到 ,获得积分10
11秒前
唠叨的夏烟完成签到 ,获得积分10
12秒前
小李子完成签到,获得积分10
12秒前
金小爬小金完成签到,获得积分10
13秒前
科研通AI2S的应助被活泼雪莲采纳,获得10
14秒前
谨慎小土豆完成签到,获得积分10
16秒前
花样年华完成签到,获得积分10
17秒前
17秒前
riooo给riooo的求助进行了留言
21秒前
FashionBoy的应助被Rei采纳,获得10
21秒前
22秒前
风趣的如萱完成签到 ,获得积分10
25秒前
2316690509完成签到 ,获得积分10
26秒前
一一完成签到,获得积分0
26秒前
木木水完成签到,获得积分10
27秒前
2010完成签到,获得积分10
30秒前
黄鹂完成签到,获得积分10
31秒前
31秒前
LLin完成签到,获得积分10
31秒前
BlossomGuard完成签到,获得积分10
34秒前
Sean完成签到 ,获得积分10
34秒前
幸福的映容完成签到 ,获得积分10
35秒前
123456789发布了新的文献求助10
37秒前
lihn完成签到,获得积分10
38秒前
Dipsy123完成签到 ,获得积分10
41秒前
CowPageant完成签到,获得积分10
42秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166550
求助须知:如何正确求助?哪些是违规求助? 9559556
关于积分的说明 21750759
捐赠科研通 7757374
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553526
邀请新用户注册赠送积分活动 2473923